Acadia Pharmaceuticals Inc. (ACAD)

[duncin_roy]

Great article on ACAD, makes you think about GALE.

ACAD's pimavanserin does have enormous peak sales potential, and anyone who reads the Seeking Alpha article will see it as a fact.

However, the same is true for GALE and NeuVax, as it treats a larger patient population that Herceptin, yet has "estimated" peak sales potential of only $2 billion. Meanwhile, Herceptin has sales of $7 billion annually.

If ACAD is the next PCYC, then GALE is the next ACAD.

http://seekingalpha.com/article/1743612-pimavanserin-the-most-underestimated-blockbuster-in-biotechnology